Chen et al. [11] detected MAGE-A3-specific CD8+ T cells in PBMCs and tumor-infiltrating lymphocytes (TILs) from ESCC patients and showed that these MAGE-A3-specific CD8+ T cells were able to respond to MAGE-A3-loaded DCs and kill human leukocyte antigen 2 (HLA-2)+MAGE-A3+ tumor cells but not HLA-2−MAGE-A3+ or MAGE-A3− tumor cells, suggesting that DC-mediated, major histocompatibility complex class 1 (MHC-I)-restricted, tumor-specific CTLs can be induced in EC patients. Here, CD8A is linked to neoplasm.